194 related articles for article (PubMed ID: 35835062)
1. Relationship between age at initiation of cysteamine treatment, adherence with therapy, and glomerular kidney function in infantile nephropathic cystinosis.
Nießl C; Boulesteix AL; Oh J; Palm K; Schlingmann P; Wygoda S; Haffner D; Wühl E; Tönshoff B; Buescher A; Billing H; Hoppe B; Zirngibl M; Kettwig M; Moeller K; Acham-Roschitz B; Arbeiter K; Bald M; Benz M; Galiano M; John-Kroegel U; Klaus G; Marx-Berger D; Moser K; Mueller D; Patzer L; Pohl M; Seitz B; Treikauskas U; von Vigier RO; Gahl WA; Hohenfellner K
Mol Genet Metab; 2022 Aug; 136(4):268-273. PubMed ID: 35835062
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis.
Hohenfellner K; Nießl C; Haffner D; Oh J; Okorn C; Palm K; Schlingmann KP; Wygoda S; Gahl WA
Mol Genet Metab; 2022 Aug; 136(4):282-288. PubMed ID: 35843134
[TBL] [Abstract][Full Text] [Related]
3. Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: A multicenter sibling cohort study.
Veys K; Zadora W; Hohenfellner K; Bockenhauer D; Janssen MCH; Niaudet P; Servais A; Topaloglu R; Besouw M; Novo R; Haffner D; Kanzelmeyer N; Pape L; Wühl E; Harms E; Awan A; Sikora P; Ariceta G; van den Heuvel B; Levtchenko E
J Inherit Metab Dis; 2023 Jan; 46(1):43-54. PubMed ID: 36117148
[TBL] [Abstract][Full Text] [Related]
4. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
Nesterova G; Williams C; Bernardini I; Gahl WA
Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological treatment of nephropathic cystinosis with cysteamine.
Kleta R; Gahl WA
Expert Opin Pharmacother; 2004 Nov; 5(11):2255-62. PubMed ID: 15500372
[TBL] [Abstract][Full Text] [Related]
6. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic challenge in a patient with nephropathic juvenile cystinosis: a case report.
Higashi S; Matsunoshita N; Otani M; Tokuhiro E; Nozu K; Ito S
BMC Nephrol; 2017 Sep; 18(1):300. PubMed ID: 28950840
[TBL] [Abstract][Full Text] [Related]
8. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.
Brodin-Sartorius A; Tête MJ; Niaudet P; Antignac C; Guest G; Ottolenghi C; Charbit M; Moyse D; Legendre C; Lesavre P; Cochat P; Servais A
Kidney Int; 2012 Jan; 81(2):179-89. PubMed ID: 21900880
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of infantile nephropathic cystinosis with cysteamine.
da Silva VA; Zurbrügg RP; Lavanchy P; Blumberg A; Suter H; Wyss SR; Lüthy CM; Oetliker OH
N Engl J Med; 1985 Dec; 313(23):1460-3. PubMed ID: 4058549
[No Abstract] [Full Text] [Related]
10. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy.
Gahl WA; Balog JZ; Kleta R
Ann Intern Med; 2007 Aug; 147(4):242-50. PubMed ID: 17709758
[TBL] [Abstract][Full Text] [Related]
11. A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis.
van Stein C; Klank S; Grüneberg M; Ottolenghi C; Grebe J; Reunert J; Harms E; Marquardt T
Orphanet J Rare Dis; 2021 Sep; 16(1):387. PubMed ID: 34521447
[TBL] [Abstract][Full Text] [Related]
12. Early oral cysteamine therapy for nephropathic cystinosis.
Gahl WA
Eur J Pediatr; 2003 Dec; 162 Suppl 1():S38-41. PubMed ID: 14610675
[TBL] [Abstract][Full Text] [Related]
13. Parenchymal organ cystine depletion with long-term cysteamine therapy.
Gahl WA; Charnas L; Markello TC; Bernardini I; Ishak KG; Dalakas MC
Biochem Med Metab Biol; 1992 Dec; 48(3):275-85. PubMed ID: 1476793
[TBL] [Abstract][Full Text] [Related]
14. Cysteamine in renal transplantation: A report of two patients with nephropathic cystinosis and the successful re-initiation of cysteamine therapy during the immediate post-transplant period.
Berryhill A; Bhamre S; Chaudhuri A; Concepcion W; Grimm PC
Pediatr Transplant; 2016 Feb; 20(1):141-5. PubMed ID: 26477696
[TBL] [Abstract][Full Text] [Related]
15. Nephropathic cystinosis: ineffectiveness of cysteamine therapy for ocular changes.
Cantani A; Giardini O; Ciarnella Cantani A
Am J Ophthalmol; 1983 May; 95(5):713-4. PubMed ID: 6846466
[TBL] [Abstract][Full Text] [Related]
16. [Cystinosis : Diagnosis, cystine-depleting therapy, and transition].
Kaufeld J; Weber LT; Kurschat C; Canaan-Kuehl S; Brand E; Oh J; Pape L
Internist (Berl); 2018 Aug; 59(8):861-867. PubMed ID: 29671012
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
[TBL] [Abstract][Full Text] [Related]
18. Impact of compliance to oral cysteamine treatment on the costs of Kidney failure in patients with nephropathic cystinosis in the United Kingdom.
Lashilola S; Xu W; Azimpour K; McCarthy M; Carlot S; Game D; van der Voort J
BMC Nephrol; 2023 Nov; 24(1):351. PubMed ID: 38031005
[TBL] [Abstract][Full Text] [Related]
19. Treatment with recombinant human growth hormone in short children with nephropathic cystinosis: no evidence for increased deterioration rate of renal function. The European Study Group on Growth Hormone Treatment in Short Children with Nephropathic Cystinosis.
Wühl E; Haffner D; Gretz N; Offner G; van't Hoff WG; Broyer M; Mehls O
Pediatr Res; 1998 Apr; 43(4 Pt 1):484-8. PubMed ID: 9545002
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
